Navigation Links
Compound from marine bacteria shows potential as multiple myeloma therapy

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

The experimental compound, NPI-0052, has been found to block or inhibit cancer cells' proteasomes from working effectively. The proteasome work as a cell's "garbage disposal," chewing up and disposing of old, unwanted proteins. With their proteasome jammed, cells die from the backup of damaged proteins.

"Proteasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of compounds in multiple myeloma. NPI-0052 is a novel proteasome inhibitor with a chemical structure and action that is distinct from bortezomib, and has the promise of being even more effective for patients," says Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and senior author of the report.

The compound will be moved into Phase I clinical trials in early 2006, say officials of Nereus Pharmaceuticals in San Diego, the developer of NPI-0052. The compound will be tested as a single agent and subsequently in combination with other treatments.

Multiple myeloma is a currently incurable cancer of the bone marrow that causes a plunge in the production of vital red and white blood cells. Although relatively rare, it is the second most common type of blood cancer and accounts for 11,000 deaths annually in the United States. Bortezomib, approved by the Food and Drug Administration in 2003 for relapsed myeloma patients and subsequently for patients who have received at least one prior treatment, demonstrated in clinical trials that it extended the time to disease progression and also improved survival.

Though less toxic than conventional chemotherapy, bortezomib does have
'"/>

Source:Dana-Farber Cancer Institute


Page: 1 2 3

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Newly Discovered Compound Blocks Known Cancer-Causing Protein
3. Compounds in plastic packaging act as environmental estrogens altering breast genes
4. Compound might defeat African sleeping sickness, clinical trial beginning this month
5. Compound from Chinese medicine shows promise in head and neck cancer
6. Anti-cancer Compound In Beer Gaining Interest
7. Compound in dairy products targets diabetes
8. Compound eyes, evolutionary ties
9. Sequencing of marine bacterium will help study of cell communication
10. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
11. UN environmental agency steps up battle against marine pollution
Post Your Comments:
(Date:5/24/2013)... Frontiers, one of the world,s largest and fastest growing ... journal, Frontiers in Physics . , A broad ... will provide an open-science and interactive web platform ... rigorously peer-reviewed articles. , Frontiers, real-time and interactive ... range of article types. With an average of three ...
(Date:5/24/2013)... After studying noise in one French Quarter neighborhood ... levels exceeded municipal ordinances, Annette Hurley, PhD, Assistant Professor ... and Eric Arriaga, a third-year LSUHSC doctor of audiology ... their own hearing health. Their case study is published ... Hearing Practice Management ., "An important part of an ...
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2
... have discovered that chickens raised for meat can choose ... towards themselves or their eggs. , That phenomenon of ... figure out how to deal with less productive hens ... own bodies. "They like to be a little bit ...
... of Michigan State University researchers will use a $4 ... the functions of genes in a plant - research ... and agriculture. , In a collaborative effort spanning several ... 4,400 nuclear genes from the Arabidopsis plant. Arabidopsis is ...
... regulates the body's main biological clocks also may play ... Southwestern Medical Center have found. , The Clock gene ... and wakefulness, body temperature, hormone levels, blood pressure and ... of the brain's reward system. , UT Southwestern researchers ...
Cached Biology News:What comes first…the chicken, the egg, or the bad attitude? 2MSU researchers receive $4 million grant to uncover gene functions 2Gene controlling circadian rhythms linked to drug addiction 2
(Date:5/23/2013)... EXTON, Pa. , May 23, 2013 /PRNewswire/ ... leading research and advisory firms for specialized biopharmaceutical ... gastroenterologists, hepatologists, and infectious disease specialists reported that ... warehousing patients (e.g., intentionally delaying treatment) in anticipation ... physicians than six months ago, when only 6 ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013  Verenium ... biotechnology company focused on the development and commercialization of ... , Chief Financial Officer, will present at two ... Mr. Black will present at the Second Annual ... at the Grand Hyatt Hotel in New York City.  ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... July 13 Instrumentation Laboratory (IL) today announced it ... recipients at the upcoming Congress for the International Society ... Meeting for the American Association for Clinical Chemistry (AACC), ... IL on July 19-23 respectively. Launched in July ...
... , ROCKVILLE, Md. , July 13 ... PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, ... with suspected central nervous system infection due to West ... company that develops immunotherapeutics to treat autoimmune disorders, cancer ...
... SYDNEY, July 12 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... to voluntarily de-list from the Nasdaq Global,Market ("Nasdaq"). , ... review of the demand from existing and,potential international investors ... on Nasdaq and the volume of Pharmaxis ADS trading,in ...
Cached Biology Technology:Instrumentation Laboratory to Announce 'Passion & Results' Award Winners 2Instrumentation Laboratory to Announce 'Passion & Results' Award Winners 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 2MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 4Pharmaxis to Voluntarily De-List from Nasdaq 2
TLN2 Antibody...
Olig2 Immunogen: Synthetic peptide from rat. Available Date: 9-19-2006...
...
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Biology Products: